2022年7月26日

保羅Schloesser副主編低價股生物技術Tonix製藥周一向美國證交會提交的文件中稱,這是結束一個授權處理啟動OyaGen紐約傳染病和腫瘤。Tonix是將許可證而OyaGen SARS-CoV-2抑製劑的候選人sangivamycin在今年4月宣布的一項協議。此舉導致Tonix TNXP美元的股價跳漲45%,結束一天的每股1.73美元。OyaGen送給Tonix選擇收購其平台的權利任何出來”的預防或治療Covid-19由OyaGen期間許可協議,”根據申請。它還規定:公司通知OyaGen其意圖終止許可協議7月22日,2022年,2022年9月20日起施行。公司重新評估其長期承諾和得出結論,符合公司的最佳利益終止許可協議和返回的開發和商業化權利sangivamycin OyaGen。Tonix還宣布,任命新浪Bavari,前者方案和科學主任美軍傳染病醫學研究所(USAMRIID),執行傳染病研發。Tonix遭到毆打在過去的幾年裏,以其領先的候選藥物tnx - 102多個III期試驗創傷後應激障礙和失敗,最近,纖維肌痛。原tnx - 102 SL的失敗,也稱為Tonmya, PTSD Tonix沉沒的股價約80%在2018年。藥物,再形成環苯紮林、肌肉鬆弛劑,FDA批準40多年前,未能改善創傷後應激障礙相比安慰劑。 Paul Schloesser Associate Editor Ginkgo Bioworks is picking up a synthetic biology competitor in what it says is its largest M&A deal yet. Ginkgo put out word early Monday it is acquiring Zymergen in an all-stock deal, valuing the Emeryville, CA-based synthetic biology biotech at around $300 million. The deal has been approved by both companies’ board of directors, and is slated to close sometime in the first quarter next year. Once done, Zymergen shareholders will own approximately 5.25% of the combined company. Keep reading Endpoints with a free subscription Unlock this story instantly and join 146,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle LaHucik Associate Editor Five years after Amgen buried its CETP cholesterol drug, a Dutch biotech with hundreds of millions in funding is headed to Wall Street to continue testing the therapy in Phase III trials. A month after spreading the news about securing $123 million upfront in an overall €1 billion deal, NewAmsterdam Pharma is back with more financing, this time from industry VC heavyweights Frazier and Bain in a deal that will take the biotech public via Frazier’s blank check company. The SPAC tie-up, which includes a PIPE, will boost NewAmsterdam’s coffers by $235 million, rounding out the company’s total cash reserves to $470 million, the companies said Monday morning. Keep reading Endpoints with a free subscription Unlock this story instantly and join 146,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Tyler Patchen News Reporter A drug developer is suing the HHS, the FDA and both its chiefs, FDA Commissioner Robert Califf and HHS Secretary Xavier Becerra, over a yearlong delay in approving a narcolepsy drug. Missouri-based Avadel CNS Pharmaceuticals filed the suit in US District Court in Washington DC accusing the agencies of stalling. The suit is based on whether the drug would infringe on one of the patents that protect Jazz Pharmaceuticals’ treatment for narcolepsy Xywav — which has been a primary treatment since 2002 and is distributed under a Risk Evaluation and Mitigation Strategy, or REMS. Keep reading Endpoints with a free subscription Unlock this story instantly and join 146,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor The star of a new Takeda campaign is an object people who suffer from inflammatory bowel disease are all too familiar with — the bathroom toilet. In the campaign, a woman sits on a toilet instead of a chair at a restaurant, in her office and in place of the driver’s seat in her car as a stark visual reminder of the multiple daily interruptions people with IBD face. The bold imagery campaign taps long-established patient insights about the burdens of IBD, which encompasses ulcerative colitis and Crohn’s disease, and the emotional and outsized role a bathroom toilet can take in their lives. Keep reading Endpoints with a free subscription Unlock this story instantly and join 146,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP